Company profile
Synlogic, Inc.
OTC: SYBX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
45DFH 50DQ 57GM 10SS 33
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, return on assets · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.0M
Employees
1
as of 2026-08-23
Market cap
$14.0M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$1.0M-$1.0M2025
Operating income-$4.0M-$4.0M2025
Total assets$15.4M$15.4M2025
Liabilities$3.8M$3.8M2016
Equity$11.9M$11.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Synlogic, Inc.’s revenue?
Synlogic, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Biomind Labs Inc.——BioCardia, Inc.29DAdagio Medical Holdings, Inc.24DPhio Pharmaceuticals Corp.41DSatellos Bioscience Inc.——Captiva Verde Wellness Corp.——Neighbors
Middlesex →Key facts
CEOMary Beth Dooley
SectorHealthcare
IndustryBiotechnology
HeadquartersWinchester, MA
ExchangeOTC: SYBX
Employees1
IPO date2015-09-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.